Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jessica A. Roseberry Baker"'
Autor:
Timothy R. Holzer, Sameera R. Wijayawardana, Gerard J. Oakley, Narasimha Marella, Holly Kay Cannon, Jessica A. Roseberry Baker, Anthony N. Sireci, Juraj Bodo, Joel D. Cook, Tyler J Marquart, Andrew E. Schade, Eric D. Hsi, Leslie O'Neill Reising
Publikováno v:
Archives of Pathology & Laboratory Medicine. 146:351-359
Context.— RET gene fusions are oncogenic drivers in nonsmall cell lung cancer and nonmedullary thyroid cancer. Selpercatinib (RETEVMO), a targeted inhibitor of RET, was approved by the US Food and Drug Administration for the treatment of RET fusion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66900a002a5c3812453106a1661a00d2
https://doi.org/10.5858/arpa.2020-0376-oa
https://doi.org/10.5858/arpa.2020-0376-oa
Autor:
Claire H. Li, Steven A. Wrighton, Jessica A. Roseberry Baker, Olukayode A. Oluyedun, Yingying Guo, Barbara J. Ring, Anne H. Dantzig, Yue-Wei Qian, Stephen D. Hall, Enaksha R Wickremsinhe
Publikováno v:
Drug Metabolism and Disposition. 41:541-545
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81358e1fe9b42b3eb56a768cb1b3acb6
https://doi.org/10.1124/dmd.112.048769
https://doi.org/10.1124/dmd.112.048769
Autor:
Holly Kay Cannon, Suzane L. Um, Jessica A. Roseberry Baker, Ruslan D. Novosiadly, Volker Wacheck, Roger Agyei, Sudhakar Chintharlapalli, Joel D. Cook, Isabella H. Wulur, William John Feaver, Ling Liu, Jennifer R. Stephens, Lysiane Huber, Linda N. Lee, Robert Evans, Sau-Chi Betty Yan, Victoria L. Peek, Liandong Ma
Publikováno v:
Cancer Research. 77:519-519
Background: MET amplification (amp) is a resistance mechanism to EGFR TKI treatment. Emibetuzumab, a bivalent MET antibody (Ab) blocks HGF binding to MET and internalizes the receptor. Combination of emibetuzumab with EGFR TKIs (erlotinib, AZD9291, C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be52eabcb80cc78e0196ad6d3709305
https://doi.org/10.1158/1538-7445.am2017-519
https://doi.org/10.1158/1538-7445.am2017-519
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 43(6)
It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to drug disposition and responses of CYP2C19 substrates during drug development. Design of such clinical trials requires projection of genotype-dependent in vivo clear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d361d35594e9406285b4b0f0009650b4
https://pubmed.ncbi.nlm.nih.gov/25845826
https://pubmed.ncbi.nlm.nih.gov/25845826
Autor:
Christophe C. Marchal, Irene Denning, Peter Edward Vaillancourt, Timothy R. Holzer, Jessica A. Roseberry Baker, Aaron M Gruver, Mark Wortinger, Jirong Lu, Julian Davies, Jeffrey C. Hanson, Sameera R. Wijayawardana, Ling Liu, Megan E Lacy, Andrew E. Schade, Hadrian P. Szpurka, Sau-Chi B. Yan, Joel D. Cook, Erin M Felke, Wei Zeng, Chi-Kin Chow, Emily Rhoads, Kelly M. Credille, Gregory Beuerlein
Publikováno v:
Histopathology. 65(6)
Development of novel targeted therapies directed against hepatocyte growth factor (HGF) or its receptor (MET) necessitates the availability of quality diagnostics to facilitate their safe and effective use. Limitations of some commercially available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49e23889656e2ea7274884c9a15c640
https://pubmed.ncbi.nlm.nih.gov/25039923
https://pubmed.ncbi.nlm.nih.gov/25039923
Autor:
Timothy R. Holzer, Jeremy R. Graff, Richard A. Walgren, Megan N. Thobe, Sau-Chi Betty Yan, Victoria L. Peek, Jessica A. Roseberry Baker, Suzane L. Um, Darryl Ballard, Jennifer R. Stephens, Kelly M. Credille, Bruce W. Konicek, Joel D. Cook, Jason Manro
Publikováno v:
Cancer Research. 74:4403-4403
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Cholangiocarcinoma (CCA) is an aggressive and locally invasive biliary tract malignancy with a poor prognosis and no approved drug treatment. LY2801653 is an orally bioavailable sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f82031becfd8d5ad347c0006ab97b17
https://doi.org/10.1158/1538-7445.am2014-4403
https://doi.org/10.1158/1538-7445.am2014-4403
Publikováno v:
Cancer Research. 72:1716-1716
Lung cancer is the leading cause of cancer-related death for both men and women in the world. FGFR receptor tyrosine kinase signaling pathway has been implicated in tumor cell growth, survival, angiogenesis, and metastasis. Activation of the FGFR pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ab2962c4481e96ceb69c03c7c366969
https://doi.org/10.1158/1538-7445.am2012-1716
https://doi.org/10.1158/1538-7445.am2012-1716